Arbutus Biopharma (ABUS) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Arbutus Biopharma is set to release its third quarter 2024 financial results and provide a corporate update on November 6, 2024. The company continues to advance its promising therapeutics for chronic hepatitis B, with key treatments in various stages of clinical trials. Investors and stakeholders can anticipate insights into the progress of their innovative RNAi therapeutic and PD-L1 inhibitor.
For further insights into ABUS stock, check out TipRanks’ Stock Analysis page.
